BIOVENTUS INC - A (BVS)
US09075A1088 - Common Stock
ChartMill assigns a Buy % Consensus number of 74% to BVS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.16. This target is 82.14% above the current price.
BVS was analyzed by 7 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about BVS.
In the previous month the buy percentage consensus was at a similar level.
BVS was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-13 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-12-07 | Canaccord Genuity | Upgrade | Hold -> Buy |
| 2023-04-03 | Craig-Hallum | Maintains | Hold |
| 2022-11-30 | Goldman Sachs | Maintains | Neutral |
| 2022-11-22 | Craig-Hallum | Downgrade | Buy -> Hold |
| 2022-11-10 | Morgan Stanley | Maintains | Overweight |
| 2022-11-09 | JP Morgan | Downgrade | Overweight -> Underweight |
| 2022-11-09 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2022-10-11 | Morgan Stanley | Maintains | Overweight |
| 2022-09-07 | Goldman Sachs | Maintains | Neutral |
| 2022-08-12 | Morgan Stanley | Maintains | Overweight |
| 2022-05-12 | Morgan Stanley | Maintains | Overweight |
| 2022-03-11 | Morgan Stanley | Maintains | Overweight |
| 2021-11-15 | Morgan Stanley | Reiterate | Overweight |
| 2021-07-01 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2021-04-19 | Morgan Stanley | Maintains | Overweight |
| 2021-03-08 | JP Morgan | Initiate | Overweight |
| 2021-03-08 | Canaccord Genuity | Initiate | Buy |
| 2021-03-08 | Goldman Sachs | Initiate | Buy |
| 2021-03-08 | Morgan Stanley | Initiate | Overweight |